Middle East and Africa Bronchiectasis Market – Industry Trends and Forecast to 2030

Middle East and Africa Bronchiectasis Market Analysis and Size

In recent times, smoking and consumption of alcohol have increased the risk of numerous kinds of lung diseases, including bronchiectasis, among others. Currently, several research studies are taking place to create a competitive advantage for manufacturers to develop new bronchiectasis drugs and diagnostic techniques, which are anticipated to increase market growth. Furthermore, antibiotics and expectorants are the main drugs available in the market for these patients.

Data Bridge Market Research analyses a growth rate in the Middle East and Africa bronchiectasis market in 2023-2030. The expected CAGR of the Middle East and Africa bronchiectasis market is around 7.2% in the mentioned forecast period. The market was valued at USD 86 million in 2022 and would grow to USD 150 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Middle East and Africa Bronchiectasis Market Scope and Segmentation

Market Definition

Bronchiectasis is a type of long-term condition where the airways of the lungs widen, leading to a build-up of excess mucus that can make the lungs more susceptible to infection. The most common symptoms associated with bronchiectasis include a persistent cough that generally brings up phlegm (sputum). A huge number of tests are performed to diagnose bronchiectasis.

Middle East and Africa Bronchiectasis Market Dynamics

Drivers

• Increasing Availability of Generic Drugs

The wide accessibility to low-cost and off-label generic drugs is one of the primary factors responsible for the market's development. Generic drugs contain the same active pharmaceutical ingredient (API) as branded drugs and are less expensive than branded drugs. The increasing availability of such low-priced drugs will surge the therapeutic adoption rates, mainly in underdeveloped and developing countries. Thus, this factor boosts market growth.

• Increasing R&D Activities Associated with Bronchiectasis

There have been growing R&D activities that are greatly enhancing the market growth. For instance, AstraZeneca received pediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol from U.S. FDA in 2017. This exclusivity confirmed the product to be safe in pediatric patients suffering from respiratory problems and inflammation. This exclusivity improved the brand value among consumers, which boosted product sales. Thus, this factor enhanced the market growth.

Opportunities

• Increasing Availability of Diagnostic Tests

There is a wide availability of diagnostic tests that are helping on a large scale in the market growth. Several tests such as chest CT scan or X-ray, blood tests and sputum cultures, lung function tests, genetic testing, and sweat chloride test help to detect the disease rapidly. A procedure called bronchoscopy is also used to look closely at the airways. Thus, this factor boosts market growth.

• Increasing Demand for Antibiotics  

There is an increasing demand for antibiotics which has led to the growth of the market. Antibiotics can treat infections caused by bacteria. It is available in pill form, but healthcare providers can use an IV to give antibiotics directly into the bloodstream in case of severe infection. Nebulizers are also used to protect patients. Thus, this factor boosts market growth.

Restraints/Challenges

• Lack of Skilled Professionals

A lack of skilled professional associated with bronchiectasis leads to market hindrance. Not all healthcare providers can handle these cases and have updated knowledge of treatments and diagnostic procedures. Thus, all these major factors impede the growth of the market.

This Middle East and Africa bronchiectasis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa bronchiectasis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Middle East and Africa Bronchiectasis Market Scope

The Middle East and Africa bronchiectasis market is segmented on the basis of disease type, severity, drugs type, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• CF Bronchiectasis
• Non-CF Bronchiectasis

Severity

• Mild to Moderate
• Moderate-to-Severe

Drug Type

• Branded
• Generics

Route of Administration

• Oral
• Parenteral
• Inhalation

End User

• Hospitals
• Clinics
• Home Health Care
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Middle East and Africa Bronchiectasis Market Regional Analysis/Insights

The Middle East and Africa bronchiectasis market is analysed and market size insights and trends are provided by disease type, severity, drugs type, route of administration, end user and distribution channel as referenced above.

The major countries covered in the Middle East and Africa bronchiectasis market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Saudi Arabia is anticipated to lead the market due to pharmaceutical leaders' increasing interest in enhancing their business in this region. Also, the increasing prevalence of fibrosis diseases among adults, particularly females, leads to market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.    

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The bronchiectasis also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for bronchiectasis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bronchiectasis market. The data is available for historic period 2011-2021.

Competitive Landscape and Middle East and Africa Bronchiectasis Market Share Analysis

The Middle East and Africa bronchiectasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Middle East and Africa bronchiectasis market

Key players operating in the Middle East and Africa bronchiectasis market include:

• Abbott (U.S.)
• HERSILL (Spain)
• Home Oxygen Company (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Medline Industries, Inc (U.S.)
• GSK plc (U.K.), AstraZeneca (U.S.)
• Pfizer Inc. (U.S.)
• Merck & Co., Inc., (U.S.)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Bayer AG (Germany)
• Zydus Pharmaceuticals, Inc. (U.S.)
• Cipla Inc. (India) 

SKU-60220